Gland Pharma appoints Wei Huang as Additional Director in category of Non-Executive, Non Independent Director

Published On 2024-11-06 07:06 GMT   |   Update On 2024-11-06 07:06 GMT
Advertisement

Telangana: Gland Pharma has announced the appointment of Wei Huang as an Additional Director in the category of Non-Executive & Non-Independent Director of the Company, liable to retire by rotation, with effect from November 04, 2024.

Wei Huang is currently the President of Shanghai Henlius Biotech Inc., responsible for the production and supply of the Company's clinical and commercial products, design and implementation of engineering projects, continuous improvement and optimization of production capacity. She is also the Chairman of Aton (Shanghai) Biotech Co., Ltd.

Advertisement

Wei Huang has leadership experience in pharmaceutical and biotechnology industry spanning over 30 years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation. She joined Fosun Pharma Group and served as Senior Vice President, Chief Operating Officer, and President of Shanghai Henlius Biotech Inc. since Dec. 2019.

Prior to that, Huang served as Chief Adviser of NEWA Technology Inc., responsible for areas such as project management, manufacturing, validation, process development and CMC, cGMP compliance audits, techno-economic assessment, gap and risk mitigation, and strategic guidance for the company. Prior to NEWA, Ms. Huang, during 2008-2013 served as Vice President of Process Development and Engineering of REG Life Sciences Corporation.

Huang holds Master’s degree from University of Maryland in Chemical and Biochemical Engineering and Bachelor’s degree from East China University of Science and Technology in Biochemical Engineering.

Read also: Gland Pharma names Shyamakant Giri as new CEO

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and develops, manufactures, and markets sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News